Brunner AM et al. Efficacy and safety of sabatolimab (MBG453) in combination with hypomethylating agents (HMAs) in patients (pts) with very high/high-risk myelodysplastic syndrome (vHR/HR-MDS) and acute myeloid leukemia (AML): Final analysis from a phase Ib study. ASH2021;Abstract 244.
Chen S et al. Venetoclax plus decitabine for young adults with newly diagnosed ELN adverse-risk acute myeloid leukemia: Interim analysis of a prospective, multicenter, single-arm, phase 2 trial. ASH 2021;Abstract 35.
Daver N et al. Phase I/II study of azacitidine (aza) with venetoclax (ven) and magrolimab (magro) in patients (pts) with newly diagnosed older/unfit or high-risk acute myeloid leukemia (AML) and relapsed/refractory (R/R) AML. ASH 2021;Abstract 371.
Daver NG et al. Tolerability and efficacy of the first-in-class Anti-CD47 antibody magrolimab combined with azacitidine in frontline patients with TP53-mutated acute myeloid leukemia: Phase Ib results. EHA 2022;Abstract S132.
Daver NG et al. Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline TP53m AML patients: Phase Ib results. ASCO 2022;Abstract 7018.
DiNardo CD et al. Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): A single-arm, phase 1b and randomised, phase 2 trial. Lancet Oncol 2021;22(11):1597-608. Abstract
Erba H et al. Quizartinib prolonged survival vs placebo plus intensive induction and consolidation therapy followed by single-agent continuation in patients aged 18-75 years with newly diagnosed FLT3-ITD+ AML. EHA 2022;Abstract S100.
Fenaux P et al. Luspatercept in patients with lower-risk myelodysplastic syndromes. N Engl J Med 2020;382(2):140-51. Abstract
Garcia JS et al. Molecular responses are observed across mutational spectrum in treatment-naïve higher-risk myelodysplastic syndrome patients treated with venetoclax plus azacitidine. ASH 2021;Abstract 241.
Garcia-Manero G et al. Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk (HR) myelodysplastic syndrome (MDS): The phase 3, randomized, ENHANCE study. ASH 2021;Abstract 3706.
Garcia-Manero G et al. Oral decitabine/cedazuridine in patients with lower risk myelodysplastic syndrome: A longer-term follow-up of from the ASCERTAIN study. ASH 2021;Abstract 66.
Konopleva M et al. Results of venetoclax and azacitidine combination in chemotherapy ineligible untreated patients with acute myeloid leukemia with FLT3 mutations. ASH 2020;Abstract 1904.
Lachowiez CA et al. A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies. ASCO 2022;Abstract 7018.
Lachowiez CA et al. A phase Ib/II Study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies. ASCO 2021;Abstract 7012.
Lancet JE et al. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older patients with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol 2021;8(7):e481-91. Abstract
Matthews A et al. Real world survival outcomes of CPX-351 versus venetoclax and azacitadine for initial therapy in adult acute myeloid leukemia. ASH 2021;Abstract 795.
Montesinos P et al. AGILE: A global, randomized, double-blind, phase 3 study of ivosidenib + azacitidine versus placebo + azacitidine in patients with newly diagnosed acute myeloid leukemia with an IDH1 mutation. ASH 2021;Abstract 697.
Perl AE et al. Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial. Blood 2022;139(23):3366-75. Abstract
Pollyea DA et al. Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase Ib study. Am J Hematol 2021;96(2):208-17. Abstract
Pratz KW et al. A phase I study of gilteritinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed AML: Final results update. EHA 2021;Abstract EP437.
Pullarkat V et al. Preliminary results of V-FAST, a phase 1b master trial to investigate CPX-351 combined with targeted agents in newly diagnosed AML. ASCO2021;Abstract 7026.
Rivera D et al. Liposomal cytarabine and daunorubicin (CPX-351) in combination with gemtuzumab ozogamicin (GO) in relapsed refractory (R/R) acute myeloid leukemia (AML) and post-hypomethylating agent (post-HMA) failure high-risk myelodysplastic syndrome (HR-MDS). ASH 2021;Abstract 2323.
Sallman DA et al. Magrolimab in combination with azacitidine for patients with untreated higher-risk myelodysplastic syndromes (HR MDS): SF9005 phase Ib results. EHA 2022;Abstract S166.
Sallman DA et al. Magrolimab in combination with azacitidine for untreated higher-risk myelodysplastic syndromes (HR MDS): SF9005 phase Ib study results. ASCO 2022;Abstract 7017.
Sallman DA et al. The first-in-class anti-CD47 antibody magrolimab combined with azacitidine is well-tolerated and effective in AML patients: Phase 1b results. ASH 2020;Abstract 330.
Sallman DA et al. Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in MDS and AML patients: Phase 1b results. ASCO 2020;Abstract 7507.
Stein EM et al. Safety and efficacy of menin inhibition in patients (pts) with MLL-rearranged and NPM1 mutant acute leukemia: A phase (ph) 1, first-in-human study of SNDX-5613 (AUGMENT 101). ASH 2021;Abstract 699.
Russell N et al. A randomised comparison of CPX-351 and FLAG-IDA in high-risk acute myeloid leukemia. Results from the NCRA AML19 trial. EHA 2022;Abstract S128.
Uy et al. Transplant outcomes after CPX-351 vs 7+3 in older adults with newly diagnosed high-risk and/or secondary AML. Blood Adv 2022;[Online ahead of print]. Abstract
Venugopal S et al. Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy. Blood Cancer J 2022;12(1):10. Abstract
Wang ES et al. Impact of FLT3 mutation clearance after front-line treatment with gilteritinib plus azacitidine, or gilteritinib or azacitidine alone in patients with newly diagnosed AML: Results from the phase 2/3 LACEWING trial. ASH 2021;Abstract 3445.
Wang J et al. Gilteritinib versus salvage chemotherapy for relapsed/refractory FLT3-mutated acute myeloid leukemia: A phase 3, randomized, multicenter, open-label trial in Asia. ASH 2021;Abstract 695.
Wei AH et al. 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy (141/150). Blood Cancer J 2021;11(10):163. Abstract
Wei AH et al. Long-term overall survival (OS) with oral azacitidine (oral-AZA) in patients with acute myeloid leukemia (AML) in first remission after intensive chemotherapy (IC): Updated results from the phase 3 QUAZAR AML-001 trial. ASH 2021;Abstract 871.
Yilmaz M et al. Quizartinib with decitabine and venetoclax (triplet) is active in patients with FLT3-ITD mutated acute myeloid leukemia – A phase I/II study. EHA 2022;Abstract S127.
Zeidan AMZ et al. Phase 3 VERONA study of venetoclax with azacitidine to assess change in complete remission and overall survival in treatment-naïve higher-risk myelodysplastic syndromes. ASCO 2021;Abstract TPS7054.